|Mr. Martin Tindall||Founder, CEO & Director||N/A||N/A||N/A|
|Mr. Geoff Boynton||CFO, Company Sec. & Director||N/A||N/A||N/A|
|Mr. Stephen Cornford||Advisor, Director of Investment & Audit and Director||N/A||N/A||N/A|
|Ms. Janelle Marsden||MD & Director||N/A||N/A||N/A|
|Mr. John M. Taleo||Global Head of Security||N/A||N/A||N/A|
Phoenix Life Sciences International Limited operates as a healthcare solutions company in the United States and internationally. It focuses on advancing research, integrating programs, and manufacturing of products that target and treat diabetes, pain, and cancer, as well as address psychological, gastrointestinal, autoimmune, neurological, and sleep disorders. The company offers transdermal patches, medi-strips, capsules, vaporizing pharmaceutical grade cannabis, and medi-mist oral sprays, as well as soft gel capsules, thin film dissolvable strips, sublingual oral sprays, suppositories, and topical creams. It is also involved in the distribution of medical cannabis-based products. The company was formerly known as Stem Bioscience, Inc. and changed its name to Phoenix Life Sciences International Limited in May 2018. The company was incorporated in 2009 and is headquartered in Denver, Colorado.
Phoenix Life Sciences International Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.